Defining Seropositivity Thresholds for Use in Trachoma Elimination Studies
- PMID: 28099433
- PMCID: PMC5242428
- DOI: 10.1371/journal.pntd.0005230
Defining Seropositivity Thresholds for Use in Trachoma Elimination Studies
Abstract
Background: Efforts are underway to eliminate trachoma as a public health problem by 2020. Programmatic guidelines are based on clinical signs that correlate poorly with Chlamydia trachomatis (Ct) infection in post-treatment and low-endemicity settings. Age-specific seroprevalence of anti Ct Pgp3 antibodies has been proposed as an alternative indicator of the need for intervention. To standardise the use of these tools, it is necessary to develop an analytical approach that performs reproducibly both within and between studies.
Methodology: Dried blood spots were collected in 2014 from children aged 1-9 years in Laos (n = 952) and Uganda (n = 2700) and from people aged 1-90 years in The Gambia (n = 1868). Anti-Pgp3 antibodies were detected by ELISA. A number of visual and statistical analytical approaches for defining serological status were compared.
Principal findings: Seroprevalence was estimated at 11.3% (Laos), 13.4% (Uganda) and 29.3% (The Gambia) by visual inspection of the inflection point. The expectation-maximisation algorithm estimated seroprevalence at 10.4% (Laos), 24.3% (Uganda) and 29.3% (The Gambia). Finite mixture model estimates were 15.6% (Laos), 17.1% (Uganda) and 26.2% (The Gambia). Receiver operating characteristic (ROC) curve analysis using a threshold calibrated against external reference specimens estimated the seroprevalence at 6.7% (Laos), 6.8% (Uganda) and 20.9% (The Gambia) when the threshold was set to optimise Youden's J index. The ROC curve analysis was found to estimate seroprevalence at lower levels than estimates based on thresholds established using internal reference data. Thresholds defined using internal reference threshold methods did not vary substantially between population samples.
Conclusions: Internally calibrated approaches to threshold specification are reproducible and consistent and thus have advantages over methods that require external calibrators. We propose that future serological analyses in trachoma use a finite mixture model or expectation-maximisation algorithm as a means of setting the threshold for ELISA data. This will facilitate standardisation and harmonisation between studies and eliminate the need to establish and maintain a global calibration standard.
Conflict of interest statement
SG is employed by the commercial company IHRC, Inc. and is a contractor at the Centres for Disease Control and Prevention. The authors have declared that no competing interests exist.
Figures
References
-
- Beatty WL, Morrison RP, Byrne GI. Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbiol Rev. 1994;58: 686–99. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=372987&tool=pm... - PMC - PubMed
-
- World Health Organisation. WHO alliance for the global elimination of Blinding trachoma by the year 2020. Wkly Epidemiol Rec. 2014;96: 421–428. - PubMed
-
- World Health Organisation. WHO | Trachoma Fact sheet N 382 [Internet]. World Health Organization; 2016. [cited 12 Aug 2016]. Available: http://www.who.int/mediacentre/factsheets/fs382/en/
-
- Bourne RRA, Stevens GA, White RA, Smith JL, Flaxman SR, Price H, et al. Causes of vision loss worldwide, 1990–2010: A systematic analysis. Lancet Glob Heal. 2013;1: 339–349. - PubMed
-
- Thylefors B, Dawson CR, Jones BR, West SK, Taylor HR. A simple system for the assessment of trachoma and its complications. Bull World Health Organ. 1987;65: 477–83. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2491032&tool=p... - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
